Study Medication Adherence and Its Determinants in Chronic Disease Through the Example of Methotrexate in Chronic Inflammatory Rheumatism
NCT02926560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137
Last updated 2019-01-14
Summary
The aim of this study is
1\) To describe the level and determinants of methotrexate adherence in patients with chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthritis and psoriatic arthritis) in the department of rheumatology in the Nîmes University Hospital
Conditions
- Rheumatic Diseases
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nīmes
lead OTHER
Principal Investigators
-
Cécile Gaujoux-Viala, MD,PhD · CHU Nîmes
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-06-01
- Primary Completion
- 2018-05-30
- Completion
- 2018-05-30
Countries
- France
Study Locations
More Related Trials
-
Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation
NCT04320680 ·Status: RECRUITING ·Phase: NA
-
Weaning of Immunosuppression in Nephritis of Lupus
NCT01284725 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02794285 ·Status: COMPLETED ·Phase: PHASE3
-
Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
NCT01856569 ·Status: COMPLETED
-
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
NCT00594932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis
NCT02900443 ·Status: UNKNOWN ·Phase: PHASE4
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
NCT00774943 ·Status: COMPLETED ·Phase: PHASE1
-
Systemic Lupus Erythematosus and Accelerated Aging
NCT05698173 ·Status: RECRUITING ·Phase: NA
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort
NCT02890134 ·Status: COMPLETED
-
Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
NCT06506214 ·Status: COMPLETED
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control
NCT02890147 ·Status: COMPLETED
-
Autoantibodies Prevalence During Checkpoint Inhibitor Treatment
NCT04220034 ·Status: COMPLETED
-
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446899 ·Status: COMPLETED ·Phase: PHASE3
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:
NCT02890121 ·Status: COMPLETED
-
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446912 ·Status: COMPLETED ·Phase: PHASE3
-
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
NCT03421184 ·Status: COMPLETED ·Phase: NA
-
International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus
NCT01509989 ·Status: COMPLETED
-
Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders
NCT07037732 ·Status: RECRUITING
-
Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism
NCT05961267 ·Status: COMPLETED
-
Mycophenolate vs Azathioprin in Autoimmune Hepatitis
NCT00687180 ·Status: COMPLETED ·Phase: PHASE4
-
Alternative Care in Patients With Auto-Immune Diseases
NCT04094259 ·Status: COMPLETED
-
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT03742037 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-infection of Low-does IL-2 in SLE
NCT02932137 ·Status: COMPLETED ·Phase: NA
-
Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
NCT03920059 ·Status: TERMINATED ·Phase: PHASE4